Irish aerosol drug delivery firm rises to global Covid-19 needs

26th March 2020

Given the numbers of people globally who need and will need care to recover from Covid-19 infection, one Irish medical device firm says it may double the number of units it ships this year.

Before the current coronavirus crisis, Aerogen already provided hospitals in more than 75 countries with its world-leading aerosol drug delivery products, benefitting 10 million patients.

Aerogen CEO John Power expects the company could ship 3m or 4m units in 2020, however, up from 2m in 2019. It is also investigating how to address the global ventilator shortage by adapting non-invasive ventilation systems.

Soaring global demand 

Aerogen can be a standalone unit or built into ventilators. It not only provides an efficient and effective way to deliver drugs to patients, but its closed-circuit system means the ventilation circuit does not need to be broken for drug delivery. This means there is a lower risk of patients transmitting Covid-19 to healthcare professionals.

The company saw an initial spike in requests earlier this year from China, where it had already been working with local ventilator company Mindray before the current crisis. “Then we started seeing an uptick in business coming through them early in 2020,” said Power.

“Then the wave of demand started coming across the world. In the past few weeks, we started seeing big orders come through from ItalyGermanySpain and the UK, and demand has skyrocketed from the US in the past week. That really shows the recent change in awareness in America,” said Power.

Read more here.

More News & Events